Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.

Pediatric diabetes - 1 Sept 2013

Bellin Melena D, Laguna Theresa, Leschyshyn Janice, Regelmann Warren, Dunitz Jordan, Billings JoAnne, Moran Antoinette

Abstract excerpt

OBJECTIVE: To determine whether the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is involved in human insulin secretion by assessing the metabolic impact of the new CFTR corrector-ivacaftor. METHODS: This open-label pilot study was conducted in CF patients with the G551D mutation given new prescriptions for ivacaftor. At baseline and 4 wk after daily ivacaftor therapy, intravenous glucose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Glucose Intolerance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucose Tolerance Test

Share to Insulin-Secreting Cells

Share to Insulin Secretion

Share to Pilot Projects

Share to Prediabetic State

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 23952705
DOI: 10.1111/pedi.12026
PMCID: PMC3804832

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.PMID 23952705Read ↗

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.Semantic proximity Read ↗

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.Semantic proximity Read ↗

CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation.Semantic proximity Read ↗

Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment.Semantic proximity Read ↗

Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis.Semantic proximity Read ↗

Managing diabetes in cystic fibrosis.Semantic proximity Read ↗

Insulin production and resistance in cystic fibrosis: effect of age, disease activity, and genotype.Semantic proximity Read ↗

Islet-intrinsic effects of CFTR mutation.Semantic proximity Read ↗

Improvements in Glucose Regulation in Children and Young People with Cystic Fibrosis-Related Diabetes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor.Semantic proximity Read ↗

Preservation of β-cell Function in Pancreatic Insufficient Cystic Fibrosis With Highly Effective CFTR Modulator Therapy.Semantic proximity Read ↗

One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational StudySemantic proximity Read ↗

Evaluation of glucose tolerance and insulin secretion in cystic fibrosis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.